bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...
Forbes3h
5 Ways Entrepreneurs Can Make The Most Of Small Businesses Saturday
Small business saturday, november 25. Vector illustration of small business saturday. Holiday ... [+] concept for banner, ...
Business Insider1d
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
RJVA-002 is a locally administered AAV9 viral vector that expresses human GIP and GLP-1 hormones ... longest data to-date demonstrating the durable efficacy of RJVA-001. The poster presentation ...
Mena FN1d
Passage Bio Reports Third Quarter 2024 Financial Results And Provides Recent Business Highlights
administration of PBFT02 resulted in widespread vector distribution in the brain and spinal cord. Appointed Tom Kassberg to the company's board of directors : In September, the company announced the ...
Yahoo Finance2d
Poster Presentation at International mRNA Health Conference Showcases Clinical Evidence that PharmaJet® Delivery Systems Enable mRNA Vaccine Delivery
PharmaJet needle-free delivery enhances immune response and provides safety, efficacy, efficiency, and patient comfort for ...
manilatimes6d
Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial
Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, 'off-the-shelf' cancer vaccine, designed to save lives by preventing disease recurrence in first-line ...
Imunon presents data from Phase 2 OVATION 2 clinical trial
IMUNON (IMNN) announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its ...